Saltar al contenido
Merck

Modeling Type 1 Diabetes In Vitro Using Human Pluripotent Stem Cells.

Cell reports (2020-07-16)
Nayara C Leite, Elad Sintov, Torsten B Meissner, Michael A Brehm, Dale L Greiner, David M Harlan, Douglas A Melton
RESUMEN

Understanding the root causes of autoimmune diseases is hampered by the inability to access relevant human tissues and identify the time of disease onset. To examine the interaction of immune cells and their cellular targets in type 1 diabetes, we differentiated human induced pluripotent stem cells into pancreatic endocrine cells, including β cells. Here, we describe an in vitro platform that models features of human type 1 diabetes using stress-induced patient-derived endocrine cells and autologous immune cells. We demonstrate a cell-type-specific response by autologous immune cells against induced pluripotent stem cell-derived β cells, along with a reduced effect on α cells. This approach represents a path to developing disease models that use patient-derived cells to predict the outcome of an autoimmune response.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Ácido retinoico, ≥98% (HPLC), powder
Sigma-Aldrich
Thapsigargin, ≥98% (HPLC), solid film
Sigma-Aldrich
LDN193189 hydrochloride, ≥98% (HPLC)
Sigma-Aldrich
Phorbol-12,13-dibutyrate, Strong irritant for mouse skin, but only moderately active as a tumor promoter.